Advertisement

Lipids

, 42:1011 | Cite as

Bioequivalence of Docosahexaenoic Acid from Different Algal Oils in Capsules and in a DHA-Fortified Food

  • Linda M. Arterburn
  • Harry A. Oken
  • James P. HoffmanEmail author
  • Eileen Bailey-Hall
  • Gloria Chung
  • Dror Rom
  • Jacqueline Hamersley
  • Deanna McCarthy
Original Article

Abstract

Docosahexaenoic acid (DHA), a long-chain omega-3 fatty acid, is important for eye and brain development and ongoing visual, cognitive, and cardiovascular health. Unlike fish-sourced oils, the bioavailability of DHA from vegetarian-sourced (algal) oils has not been formally assessed. We assessed bioequivalence of DHA oils in capsules from two different algal strains versus bioavailability from an algal-DHA-fortified food. Our 28-day randomized, placebo-controlled, parallel group study compared bioavailability of (a) two different algal DHA oils in capsules (“DHASCO-T” and “DHASCO-S”) at doses of 200, 600, and 1,000 mg DHA per day (n = 12 per group) and of (b) an algal-DHA-fortified food (n = 12). Bioequivalence was based on changes in plasma phospholipid and erythrocyte DHA levels. Effects on arachidonic acid (ARA), docosapentaenoic acid-n-6 (DPAn-6), and eicosapentaenoic acid (EPA) were also determined. Both DHASCO-T and DHASCO-S capsules produced equivalent DHA levels in plasma phospholipids and erythrocytes. DHA response was dose-dependent and linear over the dose range, plasma phospholipid DHA increased by 1.17, 2.28 and 3.03 g per 100 g fatty acid at 200, 600, and 1,000 mg dose, respectively. Snack bars fortified with DHASCO-S oil also delivered equivalent amounts of DHA on a DHA dose basis. Adverse event monitoring revealed an excellent safety and tolerability profile. Two different algal oil capsule supplements and an algal oil-fortified food represent bioequivalent and safe sources of DHA.

Keywords

Algal DHA oil Bioequivalence LCPUFA Arachidonic acid DPAn-6 Fortified foods 

Notes

Acknowledgments

We would like to acknowledge Lynne Jones for technical assistance with the study and Matt Hudson for performing statistical analyses. L. Arterburn designed the study, analyzed data, and wrote the manuscript. J. Hoffman conducted the safety assessment and assisted with writing the manuscript. Eileen Bailey-Hall and G. Chung performed the fatty acid analyses. D. McCarthy monitored the conduct of the study. H. Oken was the principal investigator who oversaw the conduct of the study. J. Hamersley was the study coordinator who ran the study. D. Rom oversaw the statistical analyses of the data. Financial Disclosure: James P. Hoffman, Eileen Bailey-Hall, Gloria Chung, and Deanna McCarthy are employed by Martek Biosciences Corporation. Linda M. Arterburn was an employee of Martek Biosciences Corporation during the time this study was conducted and the manuscript was prepared. Harry Oken is currently a consultant to Martek Biosciences Corporation, but had no financial interest in the company at the time that the study was conducted. Dror Rom is a consulting statistician to Martek Biosciences Corporation.

Supplementary material

11745_2007_3098_MOESM1_ESM.doc (104 kb)
(DOC 104 kb)

References

  1. 1.
    McCann JC, Ames BN (2005) Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 82(2):281–295PubMedGoogle Scholar
  2. 2.
    Morale SE et al (2005) Duration of long-chain polyunsaturated fatty acids availability in the diet and visual acuity. Early Hum Dev 81(2):197–203PubMedGoogle Scholar
  3. 3.
    Fleith M, Clandinin MT (2005) Dietary PUFA for preterm and term infants: review of Clinical Studies. Crit Rev Food Sci Nutr 45:205–229PubMedCrossRefGoogle Scholar
  4. 4.
    Brenna JT (2005) Meeting report: European consensus conference on recommendations for long chain polyunsaturate consumption for pregnant and lactating women (PERILIP). ISSFAL Newslett 12(3):4–6Google Scholar
  5. 5.
    Helland IB et al (2003) Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age. Pediatrics 111(1):e39–e44PubMedCrossRefGoogle Scholar
  6. 6.
    Holub DJ, Holub BJ (2004) Omega-3 fatty acids from fish oils and cardiovascular disease. Mol Cell Biochem 263(1–2):217–225PubMedCrossRefGoogle Scholar
  7. 7.
    Mori TA, Woodman RJ (2006) The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 9(2):95–104PubMedCrossRefGoogle Scholar
  8. 8.
    Maclean CH et al (2005) Effects of omega-3 fatty acids on cognitive function with aging, dementia, and neurological diseases. Evid Rep Technol Assess (Summ) 114:1–3Google Scholar
  9. 9.
    SanGiovanni JP, Chew EY (2005) The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 24(1):87–138PubMedCrossRefGoogle Scholar
  10. 10.
    Ervin RB, Wright JD, Wang CY, Kennedy-Stephenson, J (2004) Dietary intake of fats and fatty acids for the United States population: 1999–2000. Adv Data 8(348):1–6 (Hyattsville, Maryland: National Center or Health Statistics): p. DHHS Publication No. (PHS) 2005-1250 04-0565Google Scholar
  11. 11.
    Wang C, C.M., Lichtenstein A, Balk E, Kupelnick B, DeVine D, Lawrence A, Lau J (2004) Effects of Omega-3 Fatty Acids on Cardiovascular Disease. Evid Rep Technol Assess No. 94 (Prepared by Tufts-New England Medical Center Evidence-based Practice Center, under Contract No. 290–02–0022). AHRQ Publication No. 04-E009-2. Rockville, MD: Agency for Healthcare Research and QualityGoogle Scholar
  12. 12.
    Simopoulos AP, Leaf A, Salem N Jr (2000) Workshop statement on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 63(3):119–121PubMedCrossRefGoogle Scholar
  13. 13.
    Kris-Etherton PM, Harris WS, Appel LJ (2003) Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 23(2):151–152PubMedCrossRefGoogle Scholar
  14. 14.
    FDA (2001) An important message for pregnant women and women of childbearing age who may become pregnant about the risks of mercury in fish. Center for Food Safety and Applied Nutrition, Washington DC, p 3Google Scholar
  15. 15.
    Environmental Protection Agency (2003) National advice on mercury in fish caught by family and friends: for women who are pregnant or may become pregnant, nursing mothers, and young children. EPA. p 3Google Scholar
  16. 16.
    Agren JJ et al (1996) Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr 50(11):765–71PubMedGoogle Scholar
  17. 17.
    Conquer JA et al (2000) Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males [In Process Citation]. Lipids 35(2):149–54PubMedCrossRefGoogle Scholar
  18. 18.
    Conquer JA, Holub BJ (1998) Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J Lipid Res 39(2):286–292PubMedGoogle Scholar
  19. 19.
    Conquer JA, Holub BJ (1997) Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 32(3):341–345PubMedCrossRefGoogle Scholar
  20. 20.
    Davidson MH et al (1997) Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr 16(3):236–243PubMedGoogle Scholar
  21. 21.
    Nelson GJ et al (1997) The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans. Lipids 32(11):1137–1146PubMedCrossRefGoogle Scholar
  22. 22.
    Innis SM, Hansen JW (1996) Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults. Am J Clin Nutr 64(2):159–167PubMedGoogle Scholar
  23. 23.
    Makrides M, Neumann MA, Gibson RA (1996) Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur J Clin Nutr 50(6):352–357PubMedGoogle Scholar
  24. 24.
    Stark KD, Holub BJ (2004) Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 79(5):765–773PubMedGoogle Scholar
  25. 25.
    Marangell LB et al (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160(5):996–998PubMedCrossRefGoogle Scholar
  26. 26.
    Lloyd-Still JD et al (2006) Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 22(1):36–46PubMedCrossRefGoogle Scholar
  27. 27.
    Engler MM et al (2004) Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther 42(12):672–679PubMedGoogle Scholar
  28. 28.
    Jensen CL et al (2005) Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants. Am J Clin Nutr 82(1):125–132PubMedGoogle Scholar
  29. 29.
    Voigt RG et al (2001) A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 139(2):189–196PubMedCrossRefGoogle Scholar
  30. 30.
    Birch DG (2005) A randomized placebo-controlled clinical trial of docosahexaenoic acid (DHA) supplementation for X-linked retinitis pigmentosa. Ret Degener Dis Exp Ther 28S(8):S52–S54Google Scholar
  31. 31.
    Hoffman DR et al (2004) Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHA-enriched egg yolk. J Nutr 134(9):2307–2313PubMedGoogle Scholar
  32. 32.
    Hoffman DR et al (2004) Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHA-enriched egg yolk. J Nutr 134:2307–2313PubMedGoogle Scholar
  33. 33.
    Hoffman D et al (2003) Visual function in breast-fed term infants weaned to formula with or without long-chain polyunsaturates at 4 to 6 months: a randomized clinical trial. J Pediatr 142(6):669–677PubMedCrossRefGoogle Scholar
  34. 34.
    Hoffman DR et al (2002) Post-weaning supply of docosahexaenoic acid (DHA) improves visual maturation in breast-fed term infants. Exp BiolGoogle Scholar
  35. 35.
    Clandinin MT et al (2005) Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. J Pediatr 146(4):461–468PubMedCrossRefGoogle Scholar
  36. 36.
    Boswell K et al (1996) Preclinical evaluation of single-cell oils that are highly enriched with arachidonic acid and docosahexaenoic acid. Food Chem Toxicol 34(7):585–93PubMedCrossRefGoogle Scholar
  37. 37.
    Arterburn LM et al (2000) A combined subchronic (90-day) toxicity and neurotoxicity study of a single-cell source of docosahexaenoic acid triglyceride (DHASCO oil). Food Chem Toxicol 38(1):35–49PubMedCrossRefGoogle Scholar
  38. 38.
    Arterburn LM et al (2000) A developmental safety study in rats using DHA- and ARA-rich single cell oils. Food Chem Toxicol 38(9):763–771PubMedCrossRefGoogle Scholar
  39. 39.
    Arterburn LM et al (2000) In vitro genotoxicity testing of ARASCO and DHASCO oils. Food Chem Toxicol 38:971–6PubMedCrossRefGoogle Scholar
  40. 40.
    Wibert GJ et al (1997) Evaluation of single cell sources of docosahexaenoic acid and arachidonic acid: a 4-week oral safety study in rats. Food Chem Toxicol 35(10–11):967–974PubMedCrossRefGoogle Scholar
  41. 41.
    Burns RA et al (1999) Evaluation of single-cell sources of docosahexaenoic acid and arachidonic acid: 3-month rat oral safety study with an in utero phase. Food Chem Toxicol 37(1):23–36PubMedCrossRefGoogle Scholar
  42. 42.
    FDA (2001) Agency response letter GRAS notice No. GRN 000041, in US. Food and Drug Administration, Department of Health and Human Services. http://www.cfsan.fda.gov/∼rdb/opa-g041.html
  43. 43.
    Van Elswyk ME (1997) Comparison of n-3 fatty acid sources in laying hen rations for improvement of whole egg nutritional quality: a review. Br J Nutr 78(1):S61–S69PubMedCrossRefGoogle Scholar
  44. 44.
    Sanders TAB, Miller GJ (2002) Assessment of the safety of DHA GOLD oil, an algal source of docosahexaenoic acid in human subjects. Martek Internal FilesGoogle Scholar
  45. 45.
    Sanders TA et al (2006) Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr 95(3):525–531PubMedCrossRefGoogle Scholar
  46. 46.
    Maki KVE, M E, McCarthy D, Hess SP, Veith PE, Bell MV, Subbaiah PV, Davidson MH (2005) Lipid responses to a dietary docosahexaenoic acid supplement in men and women with low levels of high density lipoprotein cholesterol. J Am Coll Nutr 24(2005):189–199PubMedGoogle Scholar
  47. 47.
    Hammond BG et al (2001) Safety assessment of DHA-rich microalgae from schizochytrium sp. Part III. Single generation rat reproduction study. Regul Toxicol Pharmacol 33(3):356–362PubMedCrossRefGoogle Scholar
  48. 48.
    Hammond BG et al (2001) Safety assessment of DHA-rich microalgae from schizochytrium sp. Part II. Developmental toxicity evaluation in rats and rabbits. Regul Toxicol Pharmacol 33(2):205–217PubMedCrossRefGoogle Scholar
  49. 49.
    Hammond BG et al (2001) Safety assessment of DHA-rich microalgae from schizochytrium sp Part I. Subchronic rat feeding study. Regul Toxicol Pharmacol 33(2):192–204PubMedCrossRefGoogle Scholar
  50. 50.
    Hammond BG et al (2002) Safety assessment of DHA-rich microalgae from schizochytrium sp. Part IV. Mutagenicity studies. Regul Toxicol Pharmacol 35(2 Pt 1):255–265PubMedCrossRefGoogle Scholar
  51. 51.
    FDA, Agency response letter Gras Notification No. GRN000137, in US (2004) Food and Drug Administration, Department of Health and Human Services. http://www.cfsan.fda.gov/∼rdb/opa-g137.html
  52. 52.
    Benisek D et al (2002) Validation of a simple food frequency questionnaire as an indicator of long chain omega-3 intake (abstr). Inform 2002. Abstracts of the 93rd Annual AOCS Meeting and Expo, Montreal, Quebec, Canada, p S96Google Scholar
  53. 53.
    Folch J, Lees M, Sloane Stanley G (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226(1):497–509PubMedGoogle Scholar
  54. 54.
    Bligh EG, Dyer WJ (1954) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917Google Scholar
  55. 55.
    FDA (1992) Guidance for industry: statistical procedures for bioequivalence studies using a standard two-treatment cross-over design. US Department of Health and Human Services, Drug Information Branch, Center for Drug Evaluation and ResearchGoogle Scholar
  56. 56.
    Visioli F et al (2003) Dietary intake of fish versus formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids 38(4):415–418PubMedCrossRefGoogle Scholar
  57. 57.
    FDA (2002) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations. US Department of Health and Human Services, Center for Drug Evaluation and ResearchGoogle Scholar
  58. 58.
    Marangoni F et al (1993) Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. Biochim Biophys Acta 1210(1):55–62PubMedGoogle Scholar
  59. 59.
    Arterburn L, Hall EB, Oken H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans 1–4. Am J Clin Nutr 83(6S):1467S–1476SPubMedGoogle Scholar
  60. 60.
    Lim SY, Hoshiba J, Salem N Jr (2005) An extraordinary degree of structural specificity is required in neural phospholipids for optimal brain function: n-6 docosapentaenoic acid substitution for docosahexaenoic acid leads to a loss in spatial task performance. J Neurochem 10:1–10Google Scholar
  61. 61.
    Gronn M et al (1992) Effects of dietary purified eicosapentaenoic acid (20:5(n-3)) and docosahexaenoic acid (22:6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells. Biochim Biophys Acta 1125(1):35–43PubMedGoogle Scholar
  62. 62.
    Vidgren HM et al (1997) Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 32(7):697–705PubMedCrossRefGoogle Scholar

Copyright information

© AOCS 2007

Authors and Affiliations

  • Linda M. Arterburn
    • 1
  • Harry A. Oken
    • 2
  • James P. Hoffman
    • 1
    Email author
  • Eileen Bailey-Hall
    • 1
  • Gloria Chung
    • 1
  • Dror Rom
    • 3
  • Jacqueline Hamersley
    • 2
  • Deanna McCarthy
    • 1
  1. 1.Martek Biosciences CorporationColumbiaUSA
  2. 2.Charter Medical Group/University of MarylandBaltimoreUSA
  3. 3.Prosoft Software, IncWayneUSA

Personalised recommendations